Tempest Therapeutics Q3 net loss per share narrows on lower R&D expenses
Overview
US biotech firm posted Q3 net loss per share of $0.21, narrower than prior year
Company ended Q3 with $0.9 mln in cash, down from $7.7 mln at year-end 2025
Outlook
Company expects to present initial data from TPST-4903 Phase 1 study at upcoming conference
Investigator-initiated trial for TPST-4003 in myasthenia gravis or multiple sclerosis to begin Q4 2026
Company says existing cash expected to fund operations for less than 12 months
Result Drivers
R&D SPENDING SHIFT - Research and development expenses fell due to portfolio reprioritization after asset acquisition, offset by costs related to CAR-T candidates
HIGHER FINANCING COSTS - Financing costs rose due to commitment shares and issuance costs related to the Lincoln Park equity line of credit
PIPELINE ADVANCEMENT - Company cited progress in expanding its CAR-T pipeline and securing exclusive licensing agreements
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Loss Per Share | $0.21 |
Reuters Recommended Reads
Nov 12 - Rocket Pharmaceuticals Q3 net loss narrows as R&D costs fall
Nov 12 - Prime Medicine Q3 loss narrows as expenses decline
Nov 13 - PDS Biotechnology Q3 net loss narrows on lower R&D costs
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)